193 related articles for article (PubMed ID: 32613269)
1. Role Of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis.
Cai L; Zhao X; Ai L; Wang H
Clin Exp Med; 2020 Aug; 20(3):361-371. PubMed ID: 32613269
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the DNA methylation pathway predict clinical efficacy to hypomethylating agents in myelodysplastic syndromes: a meta-analysis.
Du M; Zhou F; Jin R; Hu Y; Mei H
Leuk Res; 2019 May; 80():11-18. PubMed ID: 30884372
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
[TBL] [Abstract][Full Text] [Related]
4. Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis.
Hu C; Wang X
Leuk Lymphoma; 2022 Oct; 63(10):2336-2351. PubMed ID: 35543621
[TBL] [Abstract][Full Text] [Related]
5. Targeting TP53 Mutations in Myelodysplastic Syndromes.
Hunter AM; Sallman DA
Hematol Oncol Clin North Am; 2020 Apr; 34(2):421-440. PubMed ID: 32089220
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in Myelodysplastic Syndromes.
Fang K; Qi J; Zhou M; Zhang Z; Han Y
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):224-235. PubMed ID: 34690091
[TBL] [Abstract][Full Text] [Related]
8. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
[TBL] [Abstract][Full Text] [Related]
9. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.
Hunter AM; Komrokji RS; Yun S; Al Ali N; Chan O; Song J; Hussaini M; Talati C; Sweet KL; Lancet JE; Padron E; List AF; Sallman DA
Blood Adv; 2021 Feb; 5(4):1017-1028. PubMed ID: 33591325
[TBL] [Abstract][Full Text] [Related]
10. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
Montalban-Bravo G; Kanagal-Shamanna R; Benton CB; Class CA; Chien KS; Sasaki K; Naqvi K; Alvarado Y; Kadia TM; Ravandi F; Daver N; Takahashi K; Jabbour E; Borthakur G; Pemmaraju N; Konopleva M; Soltysiak KA; Pierce SR; Bueso-Ramos CE; Patel KP; Kantarjian H; Garcia-Manero G
Blood Adv; 2020 Feb; 4(3):482-495. PubMed ID: 32027746
[TBL] [Abstract][Full Text] [Related]
11. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes and characteristics of patients with
Zhang L; Chen K; Li Y; Chen Q; Shi W; Ji T; Tao H; He Z; Wang C; Yu L
Hematology; 2023 Dec; 28(1):2181773. PubMed ID: 36892252
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.
Jung SH; Kim YJ; Yim SH; Kim HJ; Kwon YR; Hur EH; Goo BK; Choi YS; Lee SH; Chung YJ; Lee JH
Oncotarget; 2016 Aug; 7(34):55264-55275. PubMed ID: 27419369
[TBL] [Abstract][Full Text] [Related]
14. Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Qin Y; Kuang P; Zeng Q; Wu Y; Liu T
Ann Hematol; 2019 Nov; 98(11):2523-2531. PubMed ID: 31637485
[TBL] [Abstract][Full Text] [Related]
15. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
16. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
[TBL] [Abstract][Full Text] [Related]
17. The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.
Park HS; Son BR; Shin KS; Byeon S; Kim HK; Yang Y; Jeong Y; Han HS; Lee KH; Kwon J
Acta Haematol; 2021; 144(6):649-659. PubMed ID: 34233332
[TBL] [Abstract][Full Text] [Related]
18. Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes.
Cheng WY; Satija A; Cheung HC; Hill K; Wert T; Laliberté F; Lefebvre P
Hematology; 2021 Dec; 26(1):261-270. PubMed ID: 33631084
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Bazinet A; Desikan SP; Li Z; Rodriguez-Sevilla JJ; Venugopal S; Urrutia S; Montalban-Bravo G; Sasaki K; Chien KS; Hammond D; Kanagal-Shamanna R; Ganan-Gomez I; Kadia TM; Borthakur G; DiNardo CD; Daver NG; Jabbour EJ; Ravandi F; Kantarjian H; Garcia-Manero G
Clin Cancer Res; 2024 Apr; 30(7):1319-1326. PubMed ID: 38300723
[TBL] [Abstract][Full Text] [Related]
20. Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?
Lee EJ; Zeidan AM
Expert Rev Hematol; 2015 Apr; 8(2):155-8. PubMed ID: 25697572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
